Europe’s First Fully Integrated Organoid CRO
Humanized Multi-Organoid Disease Models operated by Dedicated Organoid Competence Centers
abc biopply AG provides validated highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis humanized multi-organoid technology™ on clinically relevant disease models (e.g. oncology, neurology, hepatic, obesity etc.)
In addition, the technology allows us to custom tailor or design any disease model and than license it to our clients for in-house implementation and scale up.
Our Integrated Organoid Services include:
- Preclinical assays: drug efficacy, safety, toxicology, IC50, dose response, relapse and resistance studies
- Disease models: oncology, neurology, hepatic, renal, and cartilage
- Custom-tailored model development and biomarker discovery
- Integrated preclinical services, from in vitro to in vivo, synchronized with humanized mouse models via our partner Preclina
Together, these offerings enable faster, more reliable drug discovery while reducing reliance on animal testing.
Organoid Service Packages
abc biopply offers a wide range of validated and standardized service packages that cover a broad range of different topics and may also include model design and characterization. Packages include:
- Drug efficacy testing (short and long range)
- Drug resistance tests
- Tumor relapse tests
- Toxicity tests, on- and off-target
- Drug safety tests
- Marker studies
- Drug tissue penetration studies
- Various omics
Integrated Study Design and Planning
All packages consist of various modules of highly specific and validated single services. Get in touch with our team of experienced organoid and preclinical study experts to get customer tailored project planning and end-point relevant results in the shortest time at reasonable costs including e.g.:
- Cell viability
- Life cell detection
- IHC/IF
- In situ hybridization
- Tissue growth
- Resistance Quantification
- Etc.
